Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 6/20 | 0.73 |
| ▸ | PDE1A | P54750 | 4/20 | 0.73 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.73 |
| ▸ | PDE2A | O00408 | 4/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 8/20 | 0.47 |
| ▸ | PDE8A | O60658 | 1/20 | 0.45 |
| ▸ | PDE5A | O76074 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.45 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3081134 | 0.94 | PDE1B (0.66) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL3079626 | 0.92 | PDE1B (0.64) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL3091517 | 0.91 | PDE1B (0.72) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL3666558 | 0.91 | PDE1B (0.72) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL193938 | 0.90 | PDE1B (0.66) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL17507919 | 0.90 | PDE1B (0.70) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL3094574 | 0.89 | PDE1B (0.76) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL3087225 | 0.89 | PDE1B (0.69) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL194205 | 0.89 | PDE1B (0.69) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL8045649 | 0.89 | PDE1B (0.64) | PDE1BPDE1APDE1CPDE2APDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2023729-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2016-05-04 | — | — | EP | claimed |
| US-9255099-B2 | Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-02-09 | — | — | US | claimed |
| EP-2400970-A1 | PDE 1 INHIBITORS FOR OPHTHALMIC DISORDERS | Intra-Cellular Therapies, Inc. (US) | 2012-01-04 | — | — | EP | claimed |
| WO-2010098839-A1 | PDE 1 INHIBITORS FOR OPHTHALMIC DISORDERS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-09-02 | — | — | WO | claimed |
| US-20100173878-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-07-08 | — | — | US | claimed |
| EP-2023729-A2 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2009-02-18 | — | — | EP | claimed |
| WO-2007143705-A2 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2007-12-13 | — | — | WO | claimed |
| EP-2023729-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2016-05-04 | — | — | EP | disclosed |
| US-9255099-B2 | Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20150197524-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197524-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2015-07-16 | — | — | US | disclosed |
| US-20100173878-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| EP-2023729-A2 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007143705-A2 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173878-A1 | ORGANIC COMPOUNDS | PDE3A, PDE7A, PDE3B | PDE1B 17/4885PDE1A 15/4885PDE1C 29/4885 |
| US-20150197524-A1 | ORGANIC COMPOUNDS | OPRD1, HTR1D, DRD1 | PDE1B 115/4885PDE1A 77/4885PDE1C 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.